FDA Inspection 1251737 — North China Pharmaceutical Huasheng Co., LTD
The FDA completed an inspection of North China Pharmaceutical Huasheng Co., LTD on Sep 6, 2024 in Shijiazhuang. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Veterinary.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 6, 2024
- Fiscal Year
- 2024
- Product Type
- Veterinary
- Project Area
- Monitoring of Marketed Animal Drugs, Feed, and Devices
- Location
- Shijiazhuang (China)